
## INTERNATIONAL SEARCH REPORT

International Application No

CLASSIFICATION OF SUBJECT MATTER PC 7 G01N33/50 G01N A. CLASS G01N33/68 A61K48/00 A61K38/00 A61K39/395 C12Q1/68 According to International Patent Classification (IPC) or to both national classification and IPC Minimum documentation searched (classification system followed by classification symbols) IPC 7 GO1N A61K C12Q C12N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE, Sequence Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Category 9 Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. χ WO 99/36550 A (INCYTE PHARMACEUTICALS, 1-26 INC; BANDMAN, OLGA; HILLMAN, JENNIFER, L; YUE,) 22 July 1999 (1999-07-22) Seq Id Nos 12 and 24, p. 25, lines 8 - 26, p. 37, line 11 - p. 38, line 20, p. 40, line 11 - p. 44, line 22, p. 48, line 5 p. 49. line 6, p. 54, line 27 - p. 55, line 13, claims 1 - 21 Α NAGASE T ET AL: "PREDICTION OF THE CODING 1-26 SEQUENCES OF UNIDENTIFIED HUMAN GENES. XI. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO" DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 5, 1998, pages 277-286, XP000828191 ISSN: 1340-2838 abstract Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the A document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed \*&\* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 1 2 07. 2005 1 March 2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Hoesel, H Fax: (+31-70) 340-3016

## INTERNATIONAL SEARCH REPORT



Box II Observations where certain claims	were found unsearchable (Continuation of item 2 of first sheet)	<del></del>
This International Search Report has not been estab	olished in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. X Claims Nos.: because they relate to subject matter not re	equired to be searched by this Authority, namely:	
Although claim 26 is direc	cted to a method of treatment of the human/animal carried out and based on the alleged effects of th	ie .
Claims Nos.: because they relate to parts of the International S an extent that no meaningful International S	onal Application that do not comply with the prescribed requirements to such	
	search can be carried out, specifically:	
Claims Nos.: because they are dependent claims and are	e not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box III Observations where unity of inventi-	on is lacking (Continuation of item 3 of first sheet)	
This International Searching Authority found multiple	inventions in this international application, as follows:	
see additional sheet		
As all required additional search fees were searchable claims.	timely paid by the applicant, this International Search Report covers all	
As all searchable claims could be searched of any additional fee.	without effort justifying an additional fee, this Authority did not invite payment	
As only some of the required additional sear covers only those claims for which fees were	rch fees were timely paid by the applicant, this International Search Report	
occord only those diams for which lees were	e paid, specifically claims Nos.:	
No required additional search fees were tim restricted to the invention first mentioned in	ely paid by the applicant. Consequently, this International Search Report is	
1-18, 24-26 (all in part);	·	
1 10, 24 20 (arr in part),	, 19-23	
B	<del>,</del>	
Remark on Protest	The additional search fees were accompanied by the applicant's protest.	
	No protest accompanied the payment of additional search fees.	
	<u>.</u>	

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-18, 24-26 (all in part.); 19-23

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with cancer

2. claims: 1-18, 24-26 (part.)

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with gastroenterological diseases, i.e. liver cirrhosis

3. claims: 1-18, 24-26 (part.)

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with hematological diseases i.e. spleen liver cirrhosis

4. claims: 1-18, 24-26 (part.)

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with neurological diseases, i.e. Alzheimer's disease

5. claims: 1-18, 24-26 (part.)

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with urological diseases, i.e. BPH

## INTERNATIONAL SEARCH REPORT



Information on patent farmily members

T/EP2004/011007

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9936550 A	22-07-1999	US AU CA EP JP WO US US	6203979 B1 2113599 A 2317094 A1 1045913 A2 2002508970 T 9936550 A2 2003166246 A1 6432690 B1 2002086334 A1	20-03-2001 02-08-1999 22-07-1999 25-10-2000 26-03-2002 22-07-1999 04-09-2003 13-08-2002 04-07-2002